HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Prochazka, A. V. Search for Related Content PubMed PubMed Citation Articles by Prochazka, A. V.

New Developments in Smoking Cessation^*

^* From the Ambulatory Care Section, Denver VA Medical Center and the Division of General Internal Medicine, University of Colorado Health Sciences Center, Denver, CO.

Correspondence to: Allan V. Prochazka, MD, MSc, Ambulatory Care 11B, Denver VA Medical Center, 1055 Clermont, Denver, CO 80220; e-mail: allan.prochazka{at}med-va.gov

Research on smoking has increased in the past several years, and many new therapeutic modalities have been developed. Primary intervention for smoking cessation begins with systematic identification of smokers and a formal diagnosis of nicotine dependence. Providing self-help brochures without clinical advice has marginal efficacy, but these can be useful as an adjunct to clinician intervention. Several large studies have shown that physician advice alone can lead to quit rates of up to 10%, and follow-up for patients trying to quit can double cessation rates. Behavioral therapy alone has demonstrated cessation rates of approximately 20% for those willing to participate. Drug therapy remains the most attractive method of smoking cessation for many patients. The standard approach has been nicotine substitution using one of the four forms of nicotine replacement (gum, patches, nasal spray, inhaler) currently available. The efficacy of nicotine replacement products is similar, with each agent providing a doubling of the cessation rate. Thus, the choice of agent depends on patient factors and preference. Bupropion is the first nonnicotine-containing agent approved for smoking cessation, with cessation rates ranging from 10.5 to 24.4%, depending on dose. One-year follow-up suggests a continued benefit with this agent. The combination of bupropion and transdermal nicotine has also been shown to be effective for smoking cessation in clinical trials. Effective approaches to smoking cessation should combine identification of smokers, provision of advice at each visit, and widespread availability of treatment.

Key Words: bupropion • drug therapy • nicotine • smoking cessation • therapy • tobacco

This article has been cited by other articles:

				B. A. Johnson New Weapon to Curb Smoking: No More Excuses to Delay Treatment. Arch Intern Med, August 14, 2006; 166(15): 1547 - 1550. [Full Text] [PDF]

				J. J. Sherman The Impact of Smoking and Quitting Smoking on Patients With Diabetes Diabetes Spectr, October 1, 2005; 18(4): 202 - 208. [Abstract] [Full Text] [PDF]

				C. Lerman, F. Patterson, and W. Berrettini Treating Tobacco Dependence: State of the Science and New Directions J. Clin. Oncol., January 10, 2005; 23(2): 311 - 323. [Abstract] [Full Text] [PDF]

				A. C. DeGraff Jr Pharmacologic Therapy for Nicotine Addiction Chest, August 1, 2002; 122(2): 392 - 394. [Full Text] [PDF]